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THE EFFICACY OF ORAL GLUTAMINE AS A PRELOADED MEDICINE IN RE-
DUCING THE SEVERITY AND DURATION OF MUCOSITIS IN THE PEDIAT-
RIC STEM CELL TRANSPLANT SETTING
Garee, A.M., Termuhlen, A.M., Skeens, M.A., Rosselet, R.M., Ryan-
Wenger, N. Nationwide Childrens Hospital, Columbus, OH
Objectives: (1) To compare the severity and duration of mucositis
during myeloablative hematopoietic stem cell transplant (HSCT) in
patients receiving glutamine starting 2 weeks prior to preparative
therapy vs. historical controls using standard mouth care without
glutamine. (2) To determine the feasibility of preloading glutamine
in pediatric patients.
Background: Mucositis is a highly debilitating complication of
myeloablative HSCT. It is associated with pain, poor oral nutri-
tional intake, diarrhea, and increased risk of infections due to
poor mucosal integrity. A randomized, placebo-controlled pediat-
ric trial demonstrated decreased mucositis scores, narcotic use,
and days of TPN with glutamine supplementation beginning
with HSCT preparative therapy (Aquino, VM (2005) a pediatric
blood and marrow transplant consortium study. Bone Marrow
Transplant Oct 36;611–6). Based on the results of that trial and
the mechanism of action of glutamine, we tested the feasibility
and efficacy of starting glutamine supplementation 2 weeks prior
to the preparative regimen.
Methods: The glutamine group (N 5 25, sequential patients)
received 2 grams/m2 qid swish and swallow of glutamine (500
mg/ml suspension) for 14 days prior to and throughout HSCT
admission. The historical control group (N 5 25, sequential
patients) received standard mouth care without glutamine begin-
ning on admission for HSCT. Data was obtained from retrospec-
tive chart review. Outcome measures include days of TPN, days
of intravenous narcotics, length of hospital stay, and mucositis
scoring.
Results:All patients preloaded with glutamine completed 14 days.
Analysis of the historical control group showed a mean of 36 days of
TPN use , a mean of 28 days of narcotic use, a mean of 49 days of
hospital stay and a mean mucositis score of 3. Data collection for
the glutamine group and the statistical analysis will be completed
in November.
Conclusions: Pediatric patients were able to complete 14 days of
glutamine prior to HSCT admission. We will report the efficacy of
glutamine compared to the historical control at the meeting. If the
glutamine group has decreased morbidity during HSCT (measured
by mucositis scores, days of narcotics, days of TPN, length of stay),
we will test the efficacy of the preloaded glutamine vs. glutamine
started concurrently with preparative therapy in a prospective ran-
domized trial.76
LONG-TERM FOLLOW-UP OF PATIENTS AFTER ALLOGENEIC HEMATO-
POIETIC STEM CELL TRANSPLANTATION (HSCT) WITH REGARD TO
QOL AND SOCIAL FUNCTIONING IN CHRONIC GVHD: A SINGLE-
INSTITUTE ANALYSIS
Mori, A.1, Yamada, M.2, Wada, N.2, Fujii, E.2, Mori, M.2,
Tanosaki, R.2, Yamamoto, S.1, Araki, M.2, Takaue, Y.2 1National Cancer
Center, Tokyo, Japan; 2National Cancer Center Hospital, Tokyo, Japan
Purpose: A single-institute evaluation of patients who underwent
allogeneic HSCT with regard to QOL, social functioning and
chronic GVHD was performed to identify a suitable long-term fol-
low-up system that is compatible with the Japanese medical environ-
ment and society.
Methods: The subjects were patients who underwent myeloabla-
tive allogeneic HSCT at our institute between January 1999 and De-
cember 2007, and who were still surviving disease-free. Chronic
GVHD was evaluated by each attending physician with the use of
NIH-GVHD. QOL was self-recorded by the patients according to
SF-36 ver2.0, FACT-BMT and FACIT-Sp12. Changes in social
function were evaluated in terms of the working status as a landmark.
This study was approval by the IRB and consent was obtained from
all patients.Results:During the study period, a total of 52 patients met the
enrollment criteria and complete data were obtained from 50 pa-
tients (96.2%) for the analysis. There were 23 males and 27 fe-
males (median age, 41 years; range, 19–56 years), with
a median follow-up of 3.6 years (0.5–8.9 years). Twenty-one pa-
tients underwent related PBSCT and 29 patients underwent
BMT (related 4, unrelated 25). Chronic GVHD was observed
in 40 patients, with an average NIH-GVHD score of 3.6 (0–
13), predominantly in the mouth and eyes. Patients who had
scores of ‘‘none’’ or ‘‘mild’’ were classified as the ‘‘observation
group’’ (23 patients, 46%), while those with ‘‘moderate’’ and ‘‘se-
vere’’ findings were classified as the ‘‘treatment group’’ (27,
54%). With regard to QOL, all of the average SF-36 subscales
were below Japanese standards. The median period required to
return to their original job was 12 months (2–24 mo), and 12 pa-
tients (24%) had variable changes in the labor status, which were
significantly related to the degree of NIH-GVHD. Factors that
significantly affected the changes in labor status and degree of
NIH-GVHD included 1) ‘‘physical functioning’’, ‘‘general
health perceptions’’ and ‘‘social functioning’’ for SF-36, 2) ‘‘total
score’’, ‘‘functional well-being’’, ‘‘emotional well-being’’ and
‘‘BMT-score’’ for FACT-BMT, and 3) ‘‘total score’’ and ‘‘mean-
ing/peace’’ for FACIT-Sp12.
Discussion: This study confirmed that NIH-GVHD may be use-
ful in the initial risk-adjusted stratification of patients for subsequent
psychosocial/spiritual follow-up and intervention in a country which
has different clinical manifestations of GVHD and a different med-
ical/social environment than in the US.77
STORIES AND MUSIC FOR ADOLESCENT/YOUNG ADULT: RESILIENCE
DURING TRANSPLANT
Haase, J.A.1, Robb, S.L.2, Burns, D.S.3, Stegenga, K.4, Haut, P.R.5,
Rimkus, C.6 1 Indiana University/ Perdue University in Indianapolis, In-
dianapolis, IN; 2 Indiana University/Perdue University in Indianapolis,
Indianapolis, IN; 3Purdue School of Engineering and Technology @ IU-
PUI, Indianapolis, IN; 4Children’s Mercy Hospital, Kansas City, MO;
5 Indiana Universtiy, Indainapolis, IN; 6Barnes-Jewish Hospital, Siteman
Cancer Center, St. Louis, MO
Adolescents and young adults (AYA) have unique concerns and
needs compared to older adults undergoing Stem Cell Transplant
(SCT). A randomized clinical trial is underway to determine if
the development of a Therapeutic Music Video (TMV) can help
AYAs (ages 11 to 24) gain resilience as an outcome of SCT. Resil-
ience is defined as positive adjustment in the face of adversity. The
study’s conceptual model identifies resources such as family envi-
ronment, adaptive coping, and social support that interact to de-
crease defensive coping, symptom distress, and uncertainty. The
TMV intervention may help AYAs undergoing SCT use music
and lyrics as a way to reflect on and work through cancer related
distresses. The major hypotheses of this study are that when com-
pared to the low-dose control, study participants who receive the
TMV will have decreased uncertainty and symptom distress and in-
creased family adaptability/cohesion and communication, perceived
social support, adaptive coping, hope, spiritual perspective, resil-
ience and quality of life. This study, administered from Indiana
University, is a cooperative effort among 3 adult and 6 children’s
hospitals at 6 medical centers across the country. Currently 80
AYA undergoing SCT have been enrolled in the study; the target
sample is 175. Participants are randomized to the TMV or audio
books condition. Regardless of group assignment, over a 3week
time period, participants have 6 one-hour meetings with a board-
certified music therapist. With help from trained evaluators, partic-
ipants also complete QOL questionnaires accessed through secure
web-sites on laptop computers. In the adult setting, clinical trials of
behavioral interventions targeting young adults (YA) are rarely
done. There are both challenges and benefits to conducting such
studies in adult hospitals. For example, AYA who are married or
have children are not eligible for the study, because their illness re-
lated concerns may be very different. A benefit is access to the re-
source of a board-certified music therapist, which may not be as
readily available in adult hospitals; both staff and the AYA patients
have enjoyed the addition of music therapy and staff have gained
opportunities to understand this patient population through their
32 Oral Presentationssharing of their TMV projects. This study is funded by the Na-
tional Institutes of Health, National Institute of Nursing Research
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PSYCHOSOCIAL ADJUSTMENT IN LONG TERM SURVIVORS OF ALLOGE-
NEIC HSCT: A COMPARISON OF PATIENTS TREATED WITH MYELOABLA-
TIVE (MC) AND REDUCED INTENSITY CONDITIONING (RIC) REGIMENS
Bevans, M.1, Mitchell, S.1, Wehrlen, L.1, Prachenko, O.1, Soeken, K.2,
Koklanaris, E.1, Cook, L.1, Odom, J.1, Prince, P.1, Le, Q.1, Castro, K.1,
Cusack, G.1, Savani, B.3, Fowler, D.1, Childs, R.1, Barrett, A.J.1 1Na-
tional Institutes of Health, Bethesda, MD; 2 Independent Consultant,
Ellicott City, MD; 3Vanderbilt University, Nashville, TN
Background: Long term survivors of allogeneic HSCT (aHSCT)
may experience significant psychosocial distress. Although factors
predicting increased distress have been reported, the influence of
conditioning intensity has not been explored.
Purpose: This analysis compares the psychosocial (PS) adjust-
ment of long term survivors who received RIC (n 5 43) or MC (n
5 77) regimens and examines predictors of PS adjustment and its re-
lationship with health-related quality of life (HRQL).
Methods: Cross-sectional data were drawn from an ongoing lon-
gitudinal study. Measures included the Psychosocial Adjustment to
Illness Scale (PAIS), the Rotterdam Symptom Checklist-physical
(RSCL-P) and the Functional Assessment of Cancer Therapy – Gen-
eral (FACT-G). Data were analyzed using descriptive statistics, cor-
relation and regression analyses.
Results: Subjects (N 5 120) were a median of 62 months from
aHSCT (range 34–156), predominantly male (59%), married
(63%), and had an ECOG status of 0 (86%). Mean scores for PS ad-
justment did not differ between the RIC (27.662.56) and MC
(26.161.82) groups (t5 4.93, p5 0.62). Age, gender, marital status,
education, employment, transplant conditioning intensity, perfor-
mance status and physical symptom distress explained 50.5% of
the variability in PAIS scores (F 5 9.30, p\0.01). Being unmarried
(b 520.169, p 5 0.044) and experiencing greater physical symptom
distress (b 5 0.609, p\0.001) independently predicted poor adjust-
ment. Poor PS adjustment was strongly associated with poor
HRQL (r520.78, p\0.001). Survivors (n5 29; 24%) with poor ad-
justment (PAIS T-score $62) reported the greatest difficulties with
family (immediate and extended) issues, sexual relationships and
psychological distress.
Conclusion: Understanding the factors that predict poor PS
adjustment in survivors of aHSCT guides assessment strategies in-
cluding approaches to systematically assess and manage distressing
symptoms. Studies to develop and test educational and counseling
interventions that optimize individual and family functioning,
including sexual relationships, in transplant recipients are
warranted.
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IMPLICATIONS FOR NURSES AND THE SUPPORTIVE CARE NEEDS FOR
CHILDREN UNDERGOING REDUCED INTENSITY CONDITIONING (RIC)
ALLOGENEIC STEM CELL TRANSPLANTATION (RIC-ALLOSCT)
Barrell, C.1, Dietzen, D.1, Shonfeld, T.1, Pinchefsky, S.1, Satwani, P.2
1Morgan Stanley Children’s Hospital of New York Presbyterian, New
York, NY; 2Columbia University, New York, NY
Allogeneic hematopoietic stem transplant (AlloSCT) is a cura-
tive option for many children with malignant and non-malignant
disorders. However, myeloablative AlloSCTs are associated with
20–40% non-relapse related mortality (NRM) in first 100 days
post AlloSCT (Satwani/Cairo et al, BBMT 2005, PBC 2007).
The morbidity and mortality associated with AlloSCT often resultin an increase in length and complexity of nursing care. However,
RIC-SCT may potentially reduce toxicities and lead to a reduction
in supportive care needs associated with an increase in nursing
care; including reduction of blood products, antibiotics, TPN,
and narcotics. There is limited data on the toxicities of RIC-Al-
loSCT in children and the impact on their nursing needs. We eval-
uated the toxicities and supportive care measures during the
conditioning regimen and 30 days post transplant required in 43
children who underwent a RIC-AlloSCT between January 2004-
March 2008 for either a malignant (n5 23) or non-malignant dis-
ease (n 5 21): Median age 10yrs (0.3- 22yrs), UCB (n 5 17),
MFD (n 5 20), MUD (n 5 6). Average risk patients (n 5 41),
poor risk (n 5 2).
Regimens: Busulfan(6.4–8mg/kg)1Fludarabine(150–180mg/m2)
6 ATG(8mg/m2) (n 5 22); Cyclophospamide(60mg/kg)1Fludara-
bine 1 (150mg/m2) 6 ATG(8mg/m2) (n 5 10); Busulfan (12.8–
16mg/kg)1Fludarabine (150mg/m2)1 Alemtuzumab (54mg/ m2)
(n 5 11). Median time to neutrophil and platelet recovery was
14.5 (8–38) and 32.5 (10–99) days, respectively. Median number of
platelet and PRBC tranfusions was 6(0–32) and 3(0–11), respectively.
The incidence of aGVHD (Gr II-IV) was 33%. One patient had pri-
mary graft failure and the incidence of VOD was zero. Median drop
in estimated CrCL from pre transplant to 30 days post was 40% (0–
68). The median highest grade of mucositis was 1 (0–3) with median
number of days on TPN 0 (0–38) and median number of days requir-
ing a PCA 0 (0–30). The median number of days with fever 3 (0–21)
and the median number of infections per patient 1 (0–2) of which 2
patients required line removal. Three patients required ICU
transfer. Day 100 NRM was 2%.
Conclusions: RIC-AlloSCT is safe, well tolerated, and associated
with significantly lower NRM. We hypothesize RIC will demon-
strate a decrease in nursing time and complexity of care. Therefore,
we are in the process of collecting data on our patients who had
a myeloablative AlloSCT to compare the incidence of various
toxicities and subsequent nursing supportive care needs to our
RIC-AlloSCT experience.80
EASING THE TBI EXPERIENCE IN THE PRE-SCHOOL PATIENT
Cash, J.V.1, Sweezy, C.M.1, Browne-Topete, A.1, Martin, P.L.1,
Georgas, D.L.2, Larrier, N.A.2 1Duke University Medical Center, Dur-
ham, NC; 2Duke University Medical Center, Durham, NC
Pediatric patients in the pre-school age group can pose
unique challenges for their care team and caregivers when un-
dergoing preparative therapy for transplantation. This is espe-
cially true when total body irradiation (TBI) is included in
the preparative regimen. Typically, TBI in the pre-school pa-
tient involves the use of general anesthesia (GA) to ensure
proper positioning, cooperation, and general patient safety.
TBI treatments at our center are given outpatient in BID frac-
tions, over 4–5 days. A consult with anesthesia is included in the
pre-transplant work-up, and the caregiver is given detailed in-
formation about keeping the child NPO for 4–6 hours, not
only once, but twice daily. As a result, many of these children
need daily IV fluids in our clinic. To address these challenges,
our center implemented a program designed to identify pre-
schoolers as potential candidates to receive their TBI treat-
ments without GA. Initial discussions between the transplant
nurse coordinator and the caregiver provide education regard-
ing TBI. The patient is then scheduled for a consultation
with the pediatric radiation oncologist. Discussion includes
the option for the patient to have a ‘‘practice’’ TBI session.
We have found this session key in identifying children who
could receive TBI without GA. The practice session involves
collaboration of skilled radiation therapy technicians and Child
Life Specialists. Age appropriate techniques are used to help
the patient practice their treatment position. The child is
taught how and why the legs and forehead may be taped to
help hold them steady. Children have the choice of watching
a favorite video, or talking to their caregiver through in inter-
com system. The treatment door is closed for 5–7 minutes, sim-
ulating an actual treatment. If the session is successful, the
